The plant of Karaganda Pharmaceutical Complex LLP began to produce two biotech drugs, such as Rituximab and Semiclotin. The first drug is an antitumor agent, and the second one is used for the treatment of patients with hemophilia.
The shops of the plant have the advanced equipment of world-class brands.
“These drugs are the innovations of domestic pharmaceutical industry. Reducing the dependence of Kazakhstan’s pharmaceutical market from imports and ensuring availability of essential medicines to the people are the priority objectives,” said Ruslan Sultanov, the President of the PharmMedIndustry of Kazakhstan Association.
The launch of manufacturing was preceded by a long stage of preclinical and clinical tests.
“This process is very complex. We are implementing the transfer of technologies that proved their effectiveness. Our strategic partner is Pharmstandart, a leader of the Russian pharmaceutical market,” said Erikbek Agatanov, the Executive Director of Karaganda Pharmaceutical Complex LLP. “We launched the pilot batches of new drugs in December 2015. This was followed by the stability studies of the medicines at the level of internal and external studies.”
The investments in the construction and equipment of the complex amounted to more than 50 million dollars. Production capacity of the plant is 4 million packages a year. According to Executive Director, the enterprise will reach this output within three years.